1. Scrip
  2. >>Business
  3. >>Deals

Despite Pfizer/Seagen’s Splash, Deals Are Staying Small

First Half 2023 Deal-Making Infographic

 
• By Joseph Haas

Although late 2022 and early 2023 saw a few large transactions, a look at deal activity in the first half of the year shows bolt-on M&A remains in vogue for biopharma. Alliances are down from first half 2022.

Year to year comparison
M&A values are up during H1 2023, but skewed by Pfizer/Seagen • Source: Shutterstock

Biopharmaceutical M&A activity started with a bang in 2023, as Pfizer Inc.’s 13 March acquisition of Seagen Inc.  for $43bn was the sector’s largest buyout since a pair of mega-mergers (Bristol Myers Squibb Company/Celgene Corporation and AbbVie Inc./Allergan plc) in 2019. That deal, combined with Merck & Co., Inc.’s $10.8bn deal for Prometheus Biosciences, Inc on 16 April and on the heels of Amgen, Inc.’s $27.8bn acquisition of Horizon Therapeutics plc announced in December 2022, raised hopes that the industry might see more major transactions. But a look at deal statistics for the first half shows that big pharma by and large remains committed to smaller acquisitions.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

Novartis Gains Further Renal Territory With Regulus Acquisition

 
• By Alaric DeArment

The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: Ferrer Signs Deal For Prilenia’s Pridopidine In Europe

 
• By Sushmita Panda

The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.

More from Business

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.